Scholarlink

Background <p>It is not clear whether septal myectomy with secondary chordal resection (SM-SCR) can achieve similar postoperative outcomes among hypertrophic obstructive cardiomyopathy (HOCM) patients exhibiting different severity of septal hypertrophy.</p> Methods <p>This was a single-center retrospective cohort study with a nested case-control study. HOCM patients received SM-SCR between 2014 and 2023 were retrospectively included and were grouped based on their septal thickness. The main outcome was the relief of the left ventricular outflow tract (LVOT) obstruction. Besides, predictors for recurrent mitral regurgitation (MR) were also explored.</p> Results <p>A total of 88 patients were included, with 63 in the significant hypertrophy group (SH group) and 25 in the mild hypertrophy group (MH group). The overall median follow-up time was 54.0 (33.0–79.0) months. Before adjusting the covariates, The LVOT gradients at the last follow-up were similar between groups [SH group vs. MH group: 10.0 (6.0–14.0) mmHg vs. 8.0 (6.0–11.5) mmHg, <i>P</i> = 0.556], while the interventricular septum (IVS) was thicker for the SH group [15.0 (12.0–17.0) mm vs. 13.0 (11.0–14.0) mm, <i>P</i> = 0.016]. In the fully adjusted model, both the LVOT gradients and the IVS thickness were comparable (<i>P</i> = 0.606 and 0.520 respectively). The risk of recurrent MR was similar between groups (7.9% vs. 8.0%, log-rank <i>P</i> = 0.879), while no predictors for recurrent MR were identified.</p> Conclusion <p>According to our single-center data, the mid-term outcomes after SM-SCR were comparable for HOCM patients with different severity of septal hypertrophy. However, further investigations with larger sample sizes and longer follow-up durations are needed.</p> Trial Registration <p>The study was approved by the Institutional Review Board [2023(2408)], and patients’ consents were waived due to the retrospective nature of the study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Myectomy with secondary chordal resection in hypertrophic obstructive cardiomyopathy: the mid-term outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Zhuheng Wu,
  • Zedong He,
  • Lin Xie,
  • Songbo Zhang,
  • Hong Qian,
  • Yajiao Li,
  • Yanlin Yang,
  • Changping Gan,
  • Ke Lin

摘要

Background

It is not clear whether septal myectomy with secondary chordal resection (SM-SCR) can achieve similar postoperative outcomes among hypertrophic obstructive cardiomyopathy (HOCM) patients exhibiting different severity of septal hypertrophy.

Methods

This was a single-center retrospective cohort study with a nested case-control study. HOCM patients received SM-SCR between 2014 and 2023 were retrospectively included and were grouped based on their septal thickness. The main outcome was the relief of the left ventricular outflow tract (LVOT) obstruction. Besides, predictors for recurrent mitral regurgitation (MR) were also explored.

Results

A total of 88 patients were included, with 63 in the significant hypertrophy group (SH group) and 25 in the mild hypertrophy group (MH group). The overall median follow-up time was 54.0 (33.0–79.0) months. Before adjusting the covariates, The LVOT gradients at the last follow-up were similar between groups [SH group vs. MH group: 10.0 (6.0–14.0) mmHg vs. 8.0 (6.0–11.5) mmHg, P = 0.556], while the interventricular septum (IVS) was thicker for the SH group [15.0 (12.0–17.0) mm vs. 13.0 (11.0–14.0) mm, P = 0.016]. In the fully adjusted model, both the LVOT gradients and the IVS thickness were comparable (P = 0.606 and 0.520 respectively). The risk of recurrent MR was similar between groups (7.9% vs. 8.0%, log-rank P = 0.879), while no predictors for recurrent MR were identified.

Conclusion

According to our single-center data, the mid-term outcomes after SM-SCR were comparable for HOCM patients with different severity of septal hypertrophy. However, further investigations with larger sample sizes and longer follow-up durations are needed.

Trial Registration

The study was approved by the Institutional Review Board [2023(2408)], and patients’ consents were waived due to the retrospective nature of the study.